Last reviewed · How we verify
Hydromorphone, Injectable
Hydromorphone is a mu-opioid receptor agonist that binds to opioid receptors in the central nervous system to produce analgesia and pain relief.
Hydromorphone is a mu-opioid receptor agonist that binds to opioid receptors in the central nervous system to produce analgesia and pain relief. Used for Moderate to severe acute pain, Moderate to severe chronic pain.
At a glance
| Generic name | Hydromorphone, Injectable |
|---|---|
| Sponsor | University of British Columbia |
| Drug class | Opioid analgesic |
| Target | Mu-opioid receptor (OPRM1) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | Phase 3 |
Mechanism of action
Hydromorphone activates mu-opioid receptors in the brain and spinal cord, inhibiting pain signal transmission and modulating pain perception. This results in potent analgesia suitable for moderate to severe pain management. The injectable formulation allows for rapid onset and flexible dosing in acute or chronic pain settings.
Approved indications
- Moderate to severe acute pain
- Moderate to severe chronic pain
Common side effects
- Respiratory depression
- Sedation
- Nausea
- Constipation
- Dizziness
- Pruritus
Key clinical trials
- Thoracic Epidural Analgesia or Four-Quadrant Transversus Abdominus Plane Block in Reducing Pain in Patients Undergoing Liver Surgery (PHASE3)
- Spinal Anesthesia For Enhanced Recovery After Liver Surgery (NA)
- Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy (PHASE2)
- Opioid-Sparing Joint Replacement (PHASE3)
- Pectoralis and Serratus Muscle Blocks (PHASE4)
- Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data (PHASE3)
- Assessing a Clinically-meaningful Opioid Withdrawal Phenotype (PHASE2)
- Hydromorphone Hydrochloride Epidural Preemptive Analgesia for Postoperative Pain After Cesarean Section (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hydromorphone, Injectable CI brief — competitive landscape report
- Hydromorphone, Injectable updates RSS · CI watch RSS
- University of British Columbia portfolio CI